post image

Global Biosimilars Market Analysis 2022-2031 by Type(Monoclonal Antibodies; Insulin; Erythropoietin; Granulocyte-Colony Stimulating Factor; Other Hormones); Application(Oncology; Chronic And Autoimmune Diseases; Growth Hormone Deficiency)

  • Report ID: 43268
  • Date: Sep, 2022
  • Pages: 287
  • Category: Healthcare & Pharmaceuticals

Biosimilars global market opportunities and strategies to 2031 from Altus Market Research provides the strategists; marketers and senior management with the critical information they need to assess the global biosimilars market as it emerges from the COVID-19 shut down.

This report describes and explains the biosimilars market and covers 2016-2021, termed the historic period, and 2021-2026 termed the forecast period, along with further forecasts for the period 2026-2031. The report evaluates the market across each region and for the major economies within each region.

The global biosimilars market reached a value of nearly $11,418.9 million in 2021, having grown at a compound annual growth rate (CAGR) of 34.8% since 2016. The market is expected to grow from $11,418.9 million in 2021 to $25,985.2 million in 2026 at a rate of 17.3%. The market is then expected to grow at a CAGR of 18.0% from 2026 and reach $59,555.8 million in 2031.

Growth in the historic period resulted from an increase in cancer prevalence, strong economic growth in emerging markets, an increase in pharmaceutical R&D expenditure, increased healthcare expenditure, growing government initiatives, strong pipeline of drugs, low cost of biosimilars and an increase in patent expiration. Factors that negatively affected growth in the historic period were regulatory changes, low healthcare access, lack of awareness on biosimilars among primary care physicians and specialists, reimbursement challenges, the coronavirus pandemic and low healthcare reimbursements.

                                                                                         

Going forward, increasing prevalence of cancer, increasing demand for prophylaxis with granulocyte colony-stimulating factor (G-CSF), a rise in healthcare expenditure, high potential of emerging economies, technology advances, high penetration of biological drugs, aging population and an increase in healthcare access will drive the growth. Factors that could hinder the growth of the biosimilars market in the future include high costs of drugs, high cost of drug development with threat of failure, pricing pressures from regulators and insufficient and outdated health system.

The biosimilars market is segmented by type into monoclonal antibodies, insulin, erythropoietin, granulocyte-colony stimulating factor, other hormones and others. The monoclonal antibodies market was the largest segment of the biosimilars market segmented by type, accounting for 39.6% of the total in 2021. Going forward, the erythropoietin segment is expected to be the fastest growing segment in the biosimilars market segmented by type, at a CAGR of 28.2% during 2021-2026.

The biosimilars market is also segmented by application into oncologychronic and autoimmune diseases, growth hormone deficiency, infectious diseases, and other applications. The chronic and autoimmune diseases market was the largest segment of the biosimilars market segmented by application, accounting for 45.6% of the total in 2021. Going forward, infectious diseases segment is expected to be the fastest growing segment in the biosimilars market segmented by end-user, at a CAGR of 24.8% during 2021-2026.

Western Europe was the largest region in the biosimilars market, accounting for 66.0% of the total in 2021. It was followed by North America, and then the other regions. Going forward, the fastest-growing regions in the biosimilars market will be Africa and Eastern Europe where growth will be at CAGRs of 117.0% and 60.1% respectively. These will be followed by South America and Middle East where the markets are expected to grow at CAGRs of 53.854% and 53.851% respectively.

The global biosimilars market is concentrated, with a small number of large players in the market. The top ten competitors in the market made up to 76.98% of the total market in 2021. The market concentration can be attributed to the high barriers to entry in terms of high costs associated with the research and development of pegfilgrastim biosimilars and the stringent regulations set up by the regulatory authorities. Going forward the market is expected some fragmentation with the rising number of new entrants. Amgen was the largest competitor with 21.23% of the market, followed by Pfizer with 13.37%, Novartis AG with 10.13%, Samsung Bioepis Co., Ltd. with 9.90%, Viatris with 7.37%, Biocon with 3.60%, Celltrion, Inc. with 3.24%, Coherus Biosciences with 4.17%, Elli Lilly and Company with 1.99%, and Dr. Reddy's Laboratories with 1.98%.

The top opportunities in the biosimilars market segmented by type will arise in the monoclonal antibodies segment, which will gain $8,508.0 million of global annual sales by 2026. The top opportunities in the biosimilars market segmented by application will arise in the oncology segment, which will gain $6,889.0 million of global annual sales by 2026. The biosimilars market size will gain the most in the USA at $6,677.4 million.

Market-trend-based strategies for the biosimilars market include focus on robust R&D activities for the development of effective and innovative drugs, focus on focus on M&A growth strategies, focus on establishing strategic partnerships, focus on increasing investments and focus on artificial intelligence.

Player-adopted strategies in the biosimilars market include strengthening product portfolio by new products launches, focusing on expansion strategies in different geographies and increasing research and development for new product development by collaborating with companies having same business.

To take advantage of the opportunities, Altus Market Research recommends the biosimilars companies to launch new products, invest in robotics and artificial intelligence (AI), expand in emerging markets, scale up through merger and acquisition activity, provide competitively priced offerings, continue to participate in events and conferences, take initiatives to educate consumers, target high-growth application areas and increase strategic partnerships.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 12 geographies.
• Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market research findings.
• Benchmark performance against key competitors.
• Utilize the relationships between key data sets for superior strategizing.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis

Description:

Where is the largest and fastest growing market for biosimilars? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The biosimilars market global report from Altus Market Research answers all these questions and many more.

The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider biosimilars market; and compares it with other markets.

The Report Covers The Following Chapters

Introduction and Market Characteristics - Brief introduction to the segmentations covered in the market, definitions and explanations about biosimilars market.

Key Trends - Highlights the major trends shaping the global biosimilars market. This section also highlights likely future developments in the market.

Global Market Size and Growth - Global historic (2016-2021) and forecast (2021-2026), and (2026-2031) market values, and drivers and restraints that support and control the growth of the market in the historic and forecast periods.

Regional Analysis - Historic (2016-2021) and forecast (2021-2026), and (2026-2031) market values and growth and market share comparison by region.

Market Segmentation - Contains the market values (2016-2031) and analysis for for segment by type, and by applications in the market.

Regional Market Size and Growth - Regional market size (2021), historic (2016-2021) and forecast (2021-2026), and (2026-2031) market values, and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.

Competitive Landscape - Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.

Biocon
Celltrion, Inc.
Coherus Biosciences
Elli Lilly and Company
Dr. Reddy's Laboratories
Roche India Pvt Ltd
Abbott India Limited
bioMérieux India
Becton Dickinson Private Limited
Danaher Corporation
Wuxi biologics
shanghai Henlius biotech
Innovent Biologics
Hisun Pharma
3SBio
Beijing ShuangLu Pharmaceuticals
Qilu Pharmaceutical
Shanghai Fosun Pharmaceuticals
Mylan
Kyowa Hakko Kirin
Takeda
Mitsubishi Tanabe
AGC Biologics
Bio-Thera
Sandoz Pty Ltd
Apotex Pty Ltd
Cadila Pharmaceuticals
BiosanaPharma
GlaxoSmithKline
AstraZeneca
Bayer
Merck
Boehringer Ingelheim
Sanofi
Fresenius Kabi
Napp Pharmaceuticals
Mundipharma Deutschland GmbH & Co. KG
HARMONIE MEDICAL SERVICE Saint-Benoît
INSULET FRANCE SAS Paris
Microgen
Geropharm
Valenta
NovaMedica
SynBio
Rani Therapeutics
Emisphere Technologies, Inc.
Enteris BioPharma
Allena Pharmaceuticals
Abbvie
Johnson & Johnson
Biogen Inc.
Aché
Eurofarma
Teva Pharmaceuticals
Oramed Pharmaceuticals
Entera Bio
Julphar
Hikma Pharmaceuticals
BIOPHARMA-MEA
NeoTX
AID Genomics Limited
Altis Biologics
Cipla Medpro South Africa
Next Biosciences
Viome
Inqaba Biotechnical Industries (Pty)

Pipeline Analysis - Briefs on the pipeline analysis of biosimilars from the major players in the market.

Key Mergers and Acquisitions - Information on recent mergers and acquisitions in the market covered in the report. This section gives key financial details of mergers and acquisitions, which have shaped the market in recent years.

Market Opportunities And Strategies - Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets.

Conclusions And Recommendations - Includes recommendations for biosimilars providers in terms of product/service offerings, geographic expansion, marketing strategies and target groups.

Appendix - This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.

Scope

Markets Covered:

1) By Type: Monoclonal Antibodies; Insulin; Erythropoietin; Granulocyte-Colony Stimulating Factor; Other Hormones; Other Types
2) By Application: Oncology; Chronic And Autoimmune Diseases; Growth Hormone Deficiency; Infectious Diseases; Other Applications

Companies Mentioned: Amgen; Pfizer; Novartis AG; Samsung Bioepis Co., Ltd.; Viatris

Countries: China; Australia; India; Indonesia; Japan; South Korea; USA; Brazil; France; Germany; UK; Russia

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; biosimilars indicators comparison.

Data segmentations: country and regional historic and forecast data; market share of competitors; market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

1. Biosimilars Market Executive Summary
2. Table of Contents
3. List of Figures
4. List of Tables
5. Report Structure
6. Introduction and Market Characteristics
6.1. General Market Definition
6.2. Summary
6.3. Market Segmentation By Type
6.3.1. Monoclonal Antibodies
6.3.2. Insulin
6.3.3. Erythropoietin
6.3.4. Granulocyte-Colony Stimulating Factor
6.3.5. Other Hormones
6.3.6. Other Types
6.4. Market Segmentation By Application
6.4.1. Oncology
6.4.2. Chronic and Autoimmune Diseases
6.4.3. Growth Hormone Deficiency
6.4.4. Infectious Diseases
6.4.5. Other Applications
7. Major Market Trends
7.1. Robust Research & Development
7.2. Demand For Biosimilars In The Treatment Of Neutropenia
7.3. Growing Mergers And Acquisitions
7.4. Revised FDA Regulations To Facilitate Biosimilar Drug Development
7.5. Large Number Of Strategic Partnerships
7.6. Increasing Investments In Biosimilars Market
7.7. Use of Robots and AI
8. Global Market Size And Growth
8.1. Market Size
8.2. Historic Market Growth, 2016 – 2021, Value ($ Million)
8.2.1. Market Drivers 2016 – 2021
8.2.2. Market Restraints 2016 – 2021
8.3. Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)
8.3.1. Market Drivers 2021 – 2026
8.3.2. Market Restraints 2021 – 2026
9. Global Biosimilars Market Segmentation
9.1. Global Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)
9.2. Global Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)
10. Biosimilars Market, Regional And Country Analysis
10.1. Global Biosimilars Market, By Region, Historic and Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)
10.2. Global Biosimilars Market, By Country, Historic and Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)
11. Asia-Pacific Market
11.1.1. Summary
11.2. Market Overview
11.2.1. Region Information
11.2.2. Market Information
11.2.3. Background Information
11.2.4. Government Initiatives
11.2.5. Regulations
11.2.6. Regulatory Bodies
11.2.7. Major Associations
11.2.8. Taxes Levied
11.2.9. Corporate Tax Structure
11.2.10. Investments
11.2.11. Major Companies
11.3. Asia-Pacific Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)
11.4. Asia-Pacific Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)
11.5. Asia-Pacific Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)
11.6. Asia-Pacific Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)
11.7. Asia-Pacific Biosimilars Market: Country Analysis
11.8. China Market
11.8.1. Summary
11.9. Market Overview
11.9.1. Country Information
11.9.2. Market Information
11.9.3. Background Information
11.9.4. Government Initiatives
11.9.5. Regulations
11.9.6. Regulatory Bodies
11.9.7. Major Associations
11.9.8. Taxes Levied
11.9.9. Corporate Tax Structure
11.9.10. Investments
11.9.11. Major Companies
11.10. China Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)
11.11. China Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)
11.12. China Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)
11.13. China Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)
11.14. India Biosimilars Market
11.15. India Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)
11.16. India Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)
11.17. India Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)
11.18. India Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)
11.19. Japan Biosimilars Market
11.20. Japan Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)
11.21. Japan Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)
11.22. Japan Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)
11.23. Japan Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)
11.24. Australia Biosimilars Market
11.25. Australia Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)
11.26. Australia Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)
11.27. Australia Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)
11.28. Australia Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)
11.29. Indonesia Biosimilars Market
11.30. Indonesia Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)
11.31. Indonesia Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)
11.32. Indonesia Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)
11.33. Indonesia Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)
11.34. South Korea Biosimilars Market
11.35. South Korea Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)
11.36. South Korea Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)
11.37. South Korea Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)
11.38. South Korea Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)
12. Western Europe Market
12.1.1. Summary
12.2. Market Overview
12.2.1. Region Information
12.2.2. Market Information
12.2.3. Background Information
12.2.4. Government Initiatives
12.2.5. Regulations
12.2.6. Regulatory bodies
12.2.7. Major Associations
12.2.8. Taxes Levied
12.2.9. Corporate Tax Structure
12.2.10. Investments
12.2.11. Major Companies
12.3. Western Europe Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)
12.4. Western Europe Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)
12.5. Western Europe Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)
12.6. Western Europe Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)
12.7. Western Europe Biosimilars Market: Country Analysis
12.8. UK Biosimilars Market
12.9. UK Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)
12.10. UK Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)
12.11. UK Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)
12.12. UK Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)
12.13. Germany Biosimilars Market
12.14. Germany Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)
12.15. Germany Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)
12.16. Germany Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)
12.17. Germany Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)
12.18. France Biosimilars Market
12.19. France Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)
12.20. France Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)
12.21. France Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)
12.22. France Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)
13. Eastern Europe Market
13.1.1. Summary
13.2. Market Overview
13.2.1. Region Information
13.2.2. Market Information
13.2.3. Background Information
13.2.4. Government Initiatives
13.2.5. Regulations
13.2.6. Regulatory Bodies
13.2.7. Major Associations
13.2.8. Taxes Levied
13.2.9. Corporate Tax Structure
13.2.10. Investments
13.2.11. Major Companies
13.3. Eastern Europe Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)
13.4. Eastern Europe Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)
13.5. Eastern Europe Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)
13.6. Eastern Europe Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)
13.7. Eastern Europe Biosimilars Market: Country Analysis
13.8. Russia Biosimilars Market
13.9. Russia Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)
13.10. Russia Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)
13.11. Russia Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)
13.12. Russia Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)
14. North America Market
14.1.1. Summary
14.2. Market Overview
14.2.1. Region Information
14.2.2. Market Information
14.2.3. Background Information
14.2.4. Government Initiatives
14.2.5. Regulations
14.2.6. Regulatory Bodies
14.2.7. Major Associations
14.2.8. Taxes Levied
14.2.9. Corporate tax structure
14.2.10. Investments
14.2.11. Major Companies
14.3. North America Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)
14.4. North America Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)
14.5. North America Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)
14.6. North America Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)
14.7. North America Biosimilars Market: Country Analysis
14.8. USA Market
14.8.1. Summary
14.9. Market Overview
14.9.1. Country Information
14.9.2. Market Information
14.9.3. Background Information
14.9.4. Government Initiatives
14.9.5. Regulations
14.9.6. Regulatory Bodies
14.9.7. Major Associations
14.9.8. Taxes Levied
14.9.9. Corporate Tax Structure
14.9.10. Investments
14.9.11. Major Companies
14.10. USA Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)
14.11. USA Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)
14.12. USA Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)
14.13. USA Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)
15. South America Market
15.1.1. Summary
15.2. Market Overview
15.2.1. Region Information
15.2.2. Market Information
15.2.3. Background Information
15.2.4. Government Initiatives
15.2.5. Regulatory Bodies
15.2.6. Regulations
15.2.7. Major Associations
15.2.8. Taxes Levied
15.2.9. Corporate Tax Structure
15.2.10. Investments
15.2.11. Major Companies
15.3. South America Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)
15.4. South America Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)
15.5. South America Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)
15.6. South America Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)
15.7. South America Biosimilars Market: Country Analysis
15.8. Brazil Biosimilars Market
15.9. Brazil Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)
15.10. Brazil Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)
15.11. Brazil Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)
15.12. Brazil Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)
16. Middle East Market
16.1.1. Summary
16.2. Market Overview
16.2.1. Region Information
16.2.2. Market Information
16.2.3. Background information
16.2.4. Government Initiatives
16.2.5. Regulatory Bodies
16.2.6. Regulations
16.2.7. Major Associations
16.2.8. Taxes Levied
16.2.9. Corporate Tax Structure
16.2.10. Investments
16.2.11. Major Companies
16.3. Middle East Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)
16.4. Middle East Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)
16.5. Middle East Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)
16.6. Middle East Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)
17. Africa Market
17.1.1. Summary
17.2. Market Overview
17.2.1. Region Information
17.2.2. Market Information
17.2.3. Background Information
17.2.4. Government Initiatives
17.2.5. Regulations
17.2.6. Regulatory Bodies
17.2.7. Major Associations
17.2.8. Taxes Levied
17.2.9. Corporate Tax Structure
17.2.10. Investments
17.2.11. Major Companies
17.3. Africa Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)
17.4. Africa Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)
17.5. Africa Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)
17.6. Africa Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)
18. Competitive Landscape And Company Profiles
18.1. Company Profiles
18.2. Amgen Inc.
18.2.1. Company Overview
18.2.2. Products And Services
18.2.3. Business Strategy
18.2.4. Financial Overview
18.3. Pfizer Inc.
18.3.1. Company Overview
18.3.2. Products And Services
18.3.3. Business Strategy
18.3.4. Financial Overview
18.4. Novartis AG
18.4.1. Company Overview
18.4.2. Products And Services
18.4.3. Business Strategy
18.4.4. Financial Overview
18.5. Samsung Bioepis Co., Ltd.
18.5.1. Company Overview
18.5.2. Products And Services
18.5.3. Business Strategy
18.5.4. Financial Overview
18.6. Viatris Inc.
18.6.1. Company Overview
18.6.2. Products And Services
18.6.3. Business Strategy
18.6.4. Financial Overview
19. Pipeline Analysis
20. Key Mergers And Acquisitions In The Biosimilars Market
20.1. Fresenius Kabi Acquired mAbxience
20.2. Biocon Biologics to Acquire Viatris Biosimilars Business
20.3. AbCellera Acquired TetraGenetics
20.4. Celltrion Acquired Assets Of Takeda Pharmaceuticals
20.5. Ligand Pharmaceuticals Acquired Pfenex
20.6. ChrysCapital Acquired Stakes In Intas Pharmaceuticals
20.7. Amgen Acquired Japanese JV with Astellas
20.8. True North Acquired Stake In Biocon Biologics Ltd.
20.9. Biocon Acquired Research and Development (R&D) Facility from Pfizer Healthcare India
20.10. PAG Acquired Hisun BioRay Bio-pharmaceutical Co., Ltd.
20.11. Pfizer Inc. Acquired Array BioPharma Inc.
20.12. Samsung Bioepis Enters Into An Agreement With C-Bridge Capital
20.13. Fuji Pharma Co., Ltd. Acquired Stake In Alvotech
20.14. Kashiv Pharma Acquired Adello Biologics
20.15. Bristol-Myers Squibb Acquired Celgene Corporation
20.16. Takeda Pharmaceutical Company Limited Acquired Shire Plc
20.17. Amneal Pharmaceuticals Merge With Impax Laboratories
20.18. Biocon Merged With Sandoz
21. Global Biosimilars Market Opportunities And Strategies
21.1. Global Biosimilars Market In 2026 – Countries Offering Most New Opportunities
21.2. Global Biosimilars Market In 2026 – Segments Offering Most New Opportunities
21.3. Global Biosimilars Market In 2026 – Growth Strategies
21.3.1. Market Trend Based Strategies
21.3.2. Competitor Strategies
22. Biosimilars Market, Conclusions And Recommendations
22.1. Conclusions
22.2. Recommendations
22.2.1. Product
22.2.2. Place
22.2.3. Price
22.2.4. Promotion
22.2.5. People
23. Appendix
23.1. Market Data Sources
23.2. Research Methodology
23.3. Currencies
23.4. The Business Research Company
24. Copyright and Disclaimer
 


List of Tables

Table 1: Global Biosimilars Market, Historic, 2016 – 2021, $ Million
Table 2: Global Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
Table 3: Global Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
Table 4: Global Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 5: Global Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
Table 6: Global Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 7: Global Biosimilars Market, By Region, Historic and Forecast, 2016 – 2021, 2026F, 2031F, %
Table 8: Global Biosimilars Market, By Region, Historic and Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 9: Global Biosimilars Market, By Country, Historic and Forecast, 2016 – 2021, 2026F, 2031F, %
Table 10: Global Biosimilars Market, By Country, Historic and Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 11: Asia-Pacific Population By Age Group, By Country, 2016-2026, Thousands
Table 12: Asia-Pacific GDP Per Capita, By Country, 2016-2021, $
Table 13: Asia-Pacific Public Healthcare Expenditure, 2015-2020, $ Billion
Table 14: Asia-Pacific Private Healthcare Expenditure, 2015-2020, $ Billion
Table 15: Asia-Pacific, Healthcare Services Market Size, By Country, 2016-2026, $ Billion
Table 16: Asia-Pacific Biosimilars Market, Historic, 2016 – 2021, $ Million
Table 17: Asia-Pacific Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
Table 18: Asia-Pacific Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
Table 19: Asia-Pacific Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 20: Asia-Pacific Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
Table 21: Asia-Pacific Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 22: China Population By Age Group, 2016-2026, Thousands
Table 23: China GDP Per Capita, 2016-2021, $
Table 24: China Public Healthcare Expenditure And Private Healthcare Expenditure, 2015-2020, $ Billion
Table 25: China Healthcare Services Market Size, By Country, 2016-2026, $ Billion
Table 26: China Biosimilars Market, Historic, 2016 – 2021, $ Million
Table 27: China Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
Table 28: China Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
Table 29: China Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 30: China Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
Table 31: China Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 32: India Biosimilars Market, Historic, 2016 – 2021, $ Million
Table 33: India Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
Table 34: India Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
Table 35: India Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 36: India Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
Table 37: India Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 38: Japan Biosimilars Market, Historic, 2016 – 2021, $ Million
Table 39: Japan Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
Table 40: Japan Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
Table 41: Japan Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 42: Japan Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
Table 43: Japan Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 44: Australia Biosimilars Market, Historic, 2016 – 2021, $ Million
Table 45: Australia Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
Table 46: Australia Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
Table 47: Australia Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 48: Australia Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
Table 49: Australia Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 50: Indonesia Biosimilars Market, Historic, 2016 – 2021, $ Million
Table 51: Indonesia Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
Table 52: Indonesia Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
Table 53: Indonesia Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 54: Indonesia Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
Table 55: Indonesia Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 56: South Korea Biosimilars Market, Historic, 2016 – 2021, $ Million
Table 57: South Korea Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
Table 58: South Korea Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
Table 59: South Korea Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 60: South Korea Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
Table 61: South Korea Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 62: Western Europe Population By Age Group, By Country, 2016-2026, Thousands
Table 63: Western Europe GDP Per Capita, By Country, 2016-2021, $
Table 64: Western Europe Public Healthcare Expenditure, 2015-2020, $ Billion
Table 65: Western Europe Private Healthcare Expenditure, 2015-2020, $ Billion
Table 66: Western Europe Healthcare Services Market Size, By Country, 2016-2026, $ Billion
Table 67: Western Europe Biosimilars Market, Historic, 2016 – 2021, $ Million
Table 68: Western Europe Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
Table 69: Western Europe Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
Table 70: Western Europe Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 71: Western Europe Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
Table 72: Western Europe Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 73: UK Biosimilars Market, Historic, 2016 – 2021, $ Million
Table 74: UK Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
Table 75: UK Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
Table 76: UK Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 77: UK Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
Table 78: UK Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 79: Germany Biosimilars Market, Historic, 2016 – 2021, $ Million
Table 80: Germany Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
Table 81: Germany Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
Table 82: Germany Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 83: Germany Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
Table 84: Germany Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 85: France Biosimilars Market, Historic, 2016 – 2021, $ Million
Table 86: France Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
Table 87: France Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
Table 88: France Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 89: France Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
Table 90: France Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 91: Eastern Europe Population By Age Group, By Country, 2016-2026, Thousands
Table 92: Eastern Europe GDP Per Capita, By Country, 2016-2021, $
Table 93: Eastern Europe Public Healthcare Expenditure, 2015-2020, $ Billion
Table 94: Eastern Europe Private Healthcare Expenditure, 2015-2020, $ Billion
Table 95: Eastern Europe Healthcare Services Market Size, By Country, 2016-2026, $ Billion
Table 96: Eastern Europe Biosimilars Market, Historic, 2016 – 2021, $ Million
Table 97: Eastern Europe Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
Table 98: Eastern Europe Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
Table 99: Eastern Europe Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 100: Eastern Europe Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
Table 101: Eastern Europe Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 102: Russia Biosimilars Market, Historic, 2016 – 2021, $ Million
Table 103: Russia Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
Table 104: Russia Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
Table 105: Russia Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 106: Russia Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
Table 107: Russia Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 108: North America Population By Age Group, By Country, 2016-2026, Thousands
Table 109: North America GDP Per Capita, By Country, 2016-2021, $
Table 110: North America Public Healthcare Expenditure, 2015-2020, $ Billion
Table 111: North America Private Healthcare Expenditure, 2015-2020, $ Billion
Table 112: North America Healthcare Services Market Size, By Country, 2016-2026, $ Billion
Table 113: North America Biosimilars Market, Historic, 2016 – 2021, $ Million
Table 114: North America Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
Table 115: North America Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
Table 116: North America Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 117: North America Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
Table 118: North America Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 119: USA Population By Age Group, 2016-2026, Thousands
Table 120: USA GDP Per Capita, 2016-2021, $
Table 121: USA Public Healthcare Expenditure And Private Healthcare Expenditure, 2015-2020, $ Billion
Table 122: USA Healthcare Services Market Size, By Country, 2016-2026, $ Billion
Table 123: USA Biosimilars Market, Historic, 2016 – 2021, $ Million
Table 124: USA Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
Table 125: USA Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
Table 126: USA Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 127: USA Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
Table 128: USA Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 129: South America Population By Age Group, By Country, 2016-2026, Thousands
Table 130: South America GDP Per Capita, By Country, 2016-2021, $
Table 131: South America Public Healthcare Expenditure, 2015-2020, $ Billion
Table 132: South America Private Healthcare Expenditure, 2015-2020, $ Billion
Table 133: South America Healthcare Services Market Size, By Country, 2016-2026, $ Billion
Table 134: South America Biosimilars Market, Historic, 2016 – 2021, $ Million
Table 135: South America Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
Table 136: South America Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
Table 137: South America Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 138: South America Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
Table 139: South America Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 140: Brazil Biosimilars Market, Historic, 2016 – 2021, $ Million
Table 141: Brazil Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
Table 142: Brazil Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
Table 143: Brazil Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 144: Brazil Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
Table 145: Brazil Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 146: Middle East Population By Age Group, By Country, 2016-2026, Thousands
Table 147: Middle East GDP Per Capita, By Country, 2016-2021, $
Table 148: Middle East Public Healthcare Expenditure, 2015-2020, $ Billion
Table 149: Middle East Private Healthcare Expenditure, 2015-2020, $ Billion
Table 150: Middle East Healthcare Services Market Size, 2016-2021, $ Billion
Table 151: Middle East Biosimilars Market, Historic, 2016 – 2021, $ Million
Table 152: Middle East Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
Table 153: Middle East Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
Table 154: Middle East Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 155: Middle East Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
Table 156: Middle East Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 157: Africa Population By Age Group, By Country, 2016-2026, Thousands
Table 158: Africa GDP Per Capita, By Country, 2016-2021, $
Table 159: Africa Public Healthcare Expenditure, 2015-2020, $ Billion
Table 160: Africa Private Healthcare Expenditure, 2015-2020, $ Billion
Table 161: Africa Healthcare Services Market Size, 2016-2021, $ Billion
Table 162: Africa Biosimilars Market, Historic, 2016 – 2021, $ Million
Table 163: Africa Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
Table 164: Africa Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
Table 165: Africa Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 166: Africa Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
Table 167: Africa Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 168: Global Smart Wearables Market, Key Competitor Estimated Market Shares, 2021, Percentage (%)
Table 169: Amgen Inc. – Financial Overview, 2017 - 2021, $ Billion
Table 170: Pfizer Inc. – Financial Overview, 2017 - 2021, $ Billion
Table 171: Novartis AG – Financial Overview, 2017 - 2021, $ Billion
Table 172: Viatris Inc. – Financial Overview, 2017 - 2021, $ Billion
Table 173: Global Biosimilars Market, Pipeline Analysis
Table 174: Global Biosimilars Market Size Gain ($ Million), 2021 – 2026, By Country
Table 175: Global Biosimilars Market Size Gain ($ Million), Segmentation By Type, 2021 – 2026
Table 176: Global Biosimilars Market Size Gain ($ Million), Segmentation By Application, 2021 – 2026
Table 177: Biosimilars Market Data Sources


List of Figures

Figure 1: Geographic Regions Covered

Figure 2: Global Biosimilars Market Segmentation By Type

Figure 3: Global Biosimilars Market Segmentation By Application

Figure 4: Global Biosimilars Market, Historic, 2016 – 2021, $ Million

Figure 5: Global Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Figure 6: Global Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 7: Global Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 8: Global Biosimilars Market, By Region, Historic and Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 9: Global Biosimilars Market, By Country, Historic and Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 10: Asia-Pacific Biosimilars Market, Historic, 2016 – 2021, $ Million

Figure 11: Asia-Pacific Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Figure 12: Asia-Pacific Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 13: Asia-Pacific Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 14: China Biosimilars Market, Historic, 2016 – 2021, $ Million

Figure 15: China Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Figure 16: China Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 17: China Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 18: India Biosimilars Market, Historic, 2016 – 2021, $ Million

Figure 19: India Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Figure 20: India Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 21: India Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 22: Japan Biosimilars Market, Historic, 2016 – 2021, $ Million

Figure 23: Japan Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Figure 24: Japan Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 25: Japan Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 26: Australia Biosimilars Market, Historic, 2016 – 2021, $ Million

Figure 27: Australia Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Figure 28: Australia Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 29: Australia Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 30: Indonesia Biosimilars Market, Historic, 2016 – 2021, $ Million

Figure 31: Indonesia Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Figure 32: Indonesia Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 33: Indonesia Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 34: South Korea Biosimilars Market, Historic, 2016 – 2021, $ Million

Figure 35: South Korea Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Figure 36: South Korea Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 37: South Korea Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 38: Western Europe Biosimilars Market, Historic, 2016 – 2021, $ Million

Figure 39: Western Europe Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Figure 40: Western Europe Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 41: Western Europe Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 42: UK Biosimilars Market, Historic, 2016 – 2021, $ Million

Figure 43: UK Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Figure 44: UK Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 45: UK Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 46: Germany Biosimilars Market, Historic, 2016 – 2021, $ Million

Figure 47: Germany Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Figure 48: Germany Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 49: Germany Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 50: France Biosimilars Market, Historic, 2016 – 2021, $ Million

Figure 51: France Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Figure 52: France Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 53: France Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 54: Eastern Europe Biosimilars Market, Historic, 2016 – 2021, $ Million

Figure 55: Eastern Europe Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Figure 56: Eastern Europe Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 57: Eastern Europe Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 58: Russia Biosimilars Market, Historic, 2016 – 2021, $ Million

Figure 59: Russia Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Figure 60: Russia Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 61: Russia Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 62: North America Biosimilars Market, Historic, 2016 – 2021, $ Million

Figure 63: North America Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Figure 64: North America Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 65: North America Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 66: USA Biosimilars Market, Historic, 2016 – 2021, $ Million

Figure 67: USA Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Figure 68: USA Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 69: USA Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 70: South America Biosimilars Market, Historic, 2016 – 2021, $ Million

Figure 71: South America Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Figure 72: South America Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 73: South America Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 74: Brazil Biosimilars Market, Historic, 2016 – 2021, $ Million

Figure 75: Brazil Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Figure 76: Brazil Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 77: Brazil Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 78: Middle East Biosimilars Market, Historic, 2016 – 2021, $ Million

Figure 79: Middle East Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Figure 80: Middle East Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 81: Middle East Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 82: Africa Biosimilars Market, Historic, 2016 – 2021, $ Million

Figure 83: Africa Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Figure 84: Africa Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 85: Africa Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 86: Global biosimilars Market, Key Competitor Estimated Market Shares, 2021, Percentage (%)

Figure 87: Amgen Inc. – Financial Overview, 2017 – 2021, $ Billion

Figure 88: Pfizer Inc. – Financial Overview, 2017 – 2021, $ Billion

Figure 89: Novartis AG – Financial Overview, 2017 – 2021, $ Billion

Figure 90: Viatris Inc. – Financial Overview, 2017 – 2021, $ Billion

Research methodology is mainly referring to the practical how of any offered piece of research. More specifically, it’s all about how a researcher systematically designs a study in order to assure extremely valid as well as reliable results that ultimately address the targets and objectives of the research.

In any formal research including academic journal, article, dissertation and so on, there will be a special section on a research methodology that mainly describes what, by whom, how to gather as well as how to evaluate the data are provided.

This research methodology has been segmented into following types:

Primary Research:

It is said to be original information that the researchers collect for the crucial purposes of answering the research questions of readers with the help of surveys, observations and experiments.

Secondary Research:

The secondary research is the data that has already been collected by various other researchers in the form of government analysis or scientific studies.

Qualitative Research:

It is descriptive and subjective method irrespective of facts. Both observation and description are essential in this type of research methodology. Its main vision is to analyze knowledge, attitudes, behaviours as well as opinions of people related to the topic of any research. This method has been operated through grounded research, case study and actionable research.

Quantitative Research:

It contains several laboratory experiments, basic surveys, mathematical calculations, simulations and so on. The possible measurement, quantity or amount is considered to be a major factor in the quantitative research methodology.

Tab Four
Our Happy

Clients